Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Viking Therapeutics has begun the VANQUISH Phase III clinical programme of the dual agonist of the glucagon-like peptide 1 ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.

Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to ...

In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer ("mCRPC"),the six-month radiographic progres ...

The trial results will support dose selection for future clinical trials. Additional information about the Phase 1a/b trial is available at clinicaltrials.gov using the identifier NCT06698575.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the. On June 4, the company published pre-specified analyses for its ...

Discover what clinical trials are, why they're vital for new treatments, and how you can participate in life-changing medical research.

In a recent regulatory development, the Subject Expert Committee (SEC) under the Dermatology and Allergy division of the ...

A phase 3 clinical trial investigating ST-100 for the treatment of dry eye disease did not meet its primary endpoint but ...